DESTINY-Breast03 Phase 3 Study Results

Case Summary: Patient With Clear Cell RCC 60-year-old man with stage IV RCC Treated with DS-6000a 3.2 mg/kg intravenously q3w 3 prior therapies • Sorafenib . Nivolumab Telaglenastat + cabozantinib Cycle 18 treatment ongoing Baseline 19 weeks 48 weeks Overall PR (-45.2%) Overall PR (-64.3%) PR, partial response; q3w, every 3 weeks; RCC, renal cell carcinoma. ASCO 2022 #3002 Oral Daiichi-Sankyo 107

View entire presentation